Prognostic Implications of Change in Left Ventricular Ejection Fraction After Transcatheter Aortic Valve Implantation.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 08 2022
Historique:
received: 23 02 2022
revised: 15 04 2022
accepted: 23 04 2022
pubmed: 13 6 2022
medline: 20 7 2022
entrez: 12 6 2022
Statut: ppublish

Résumé

Reduced left ventricular (LV) systolic function is associated with worse prognosis in patients with severe aortic stenosis (AS) treated with transcatheter aortic valve implantation (TAVI). We aimed to examine the changes in left ventricular ejection fraction (LVEF) after TAVI among patients with varying baseline LVEF. Moreover, variables associated with lack of LVEF improvement were identified and the association with long-term outcomes was investigated. A total of 560 patients (age 80 ± 7 years, 53% men) with severe AS who underwent transfemoral TAVI between 2007 and 2019 were selected. LVEF was assessed from transthoracic echocardiography at baseline (before TAVI) and at 6 and 12 months after TAVI. Patients were stratified according to baseline LVEF: (1) LVEF ≥50%, (2) LVEF 40% to 49%, and (3) LVEF <40%. The clinical end point was ≥5% LVEF improvement. The primary outcome was all-cause mortality. Patients with baseline LVEF<40% showed greater increase in LVEF than those with baseline LVEF 40% to 49% and LVEF ≥50% (from 33% ± 6% to 43% ± 10%, p <0.001; from 45% ± 3% to 52% ± 8%, p <0.001; and from 58% ± 5% to 59% ± 7%, p = 0.012, respectively, p for interaction <0.001). Coronary artery disease (odds ratio [OR] 1.80 [95% confidence interval (CI) 1.06 to 3.06], p = 0.031), myocardial infarction (OR 2.07 [95% CI 1.19 to 3.61], p = 0.010), and permanent pacemaker (OR: 1.93 [95% CI 1.25 to 3.00], p = 0.003) were independently associated with the lack of ≥5% LVEF improvement. During a median follow-up of 3.8 (interquartile range 2.6 to 5.2) years, 176 patients died (31%). Patients with ≥5% LVEF improvement had similar outcomes compared with those with <5% LVEF improvement (log-rank p = 0.89). In conclusion, patients with severe AS and baseline LVEF <40% had the greatest improvement in LVEF at 1-year follow-up after TAVI. Coronary artery disease, myocardial infarction, and permanent pacemaker were associated with lack of LVEF improvement. However, LVEF improvement at 12 months was not associated with long-term outcomes.

Identifiants

pubmed: 35691708
pii: S0002-9149(22)00537-9
doi: 10.1016/j.amjcard.2022.04.060
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-99

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Jurrien H Kuneman (JH)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Steele C Butcher (SC)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia.

Gurpreet K Singh (GK)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Xu Wang (X)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Kensuke Hirasawa (K)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Frank van der Kley (F)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Martin B Leon (MB)

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.

Juhani Knuuti (J)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.

Philippe Pibarot (P)

Department of Medicine, Québec Heart and Lung Institute, Laval University, Quebec City, Québec, Canada.

Nina Ajmone Marsan (N)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Victoria Delgado (V)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Jeroen J Bax (JJ)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; Turku Heart Center, University of Turku and Turku University Hospital, Turku, Finland. Electronic address: j.j.bax@lumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH